{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:03:08Z","timestamp":1784696588203,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T00:00:00Z","timestamp":1514505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00345-017-2163-9","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T23:48:12Z","timestamp":1514504892000},"page":"323-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0552-7402","authenticated-orcid":false,"given":"Matthew J.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick N.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Naber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian M. E.","family":"Wagenlehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhail A. R.","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,29]]},"reference":[{"issue":"5","key":"2163_CR1","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.juro.2011.06.057","volume":"186","author":"S Loeb","year":"2011","unstructured":"Loeb S et al (2011) Complications after prostate biopsy: data from SEER-Medicare. J Urol 186(5):1830\u20131834","journal-title":"J Urol"},{"key":"2163_CR2","first-page":"CD006576","volume":"5","author":"EL Zani","year":"2011","unstructured":"Zani EL, Clark OA, Netto NR Jr (2011) Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 5:CD006576","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2163_CR3","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.juro.2008.01.068","volume":"179","author":"JS Wolf Jr","year":"2008","unstructured":"Wolf JS Jr et al (2008) Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 179(4):1379\u20131390","journal-title":"J Urol"},{"issue":"4","key":"2163_CR4","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.juro.2016.11.081","volume":"197","author":"JA Halpern","year":"2016","unstructured":"Halpern JA et al (2016) Indications, utilization and complications following prostate biopsy: a New York State analysis. J Urol 197(4):1020\u20131025","journal-title":"J Urol"},{"issue":"9","key":"2163_CR5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/pros.22979","volume":"75","author":"M Aly","year":"2015","unstructured":"Aly M et al (2015) Rapid increase in multidrug-resistant enteric bacilli blood stream infection after prostate biopsy\u2014a 10-year population-based cohort study. Prostate 75(9):947\u2013956","journal-title":"Prostate"},{"issue":"3","key":"2163_CR6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.eururo.2012.04.044","volume":"62","author":"A Carignan","year":"2012","unstructured":"Carignan A et al (2012) Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? Eur Urol 62(3):453\u2013459","journal-title":"Eur Urol"},{"issue":"10","key":"2163_CR7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrurol.2015.199","volume":"12","author":"HM Zowawi","year":"2015","unstructured":"Zowawi HM et al (2015) The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol 12(10):570\u2013584","journal-title":"Nat Rev Urol"},{"issue":"4","key":"2163_CR8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.urpr.2014.10.011","volume":"2","author":"T Averch","year":"2015","unstructured":"Averch T et al (2015) AUA Quality Improvement Summit 2014: conference proceedings on infectious complications of transrectal prostate needle biopsy. Urol Pract 2(4):172\u2013180","journal-title":"Urol Pract"},{"key":"2163_CR9","doi-asserted-by":"crossref","unstructured":"Liss MA et al (2017) American Urological Association white paper on the prevention and treatment of the more common complications related to prostate biopsy update. J Urol (in press)","DOI":"10.1016\/j.juro.2017.01.103"},{"issue":"4","key":"2163_CR10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijantimicag.2014.01.008","volume":"43","author":"MJ Roberts","year":"2014","unstructured":"Roberts MJ et al (2014) Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: a bias-adjusted meta-analysis. Int J Antimicrob Agents 43(4):301\u2013309","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"2163_CR11","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/cid\/ciu1129","volume":"60","author":"MA Liss","year":"2015","unstructured":"Liss MA et al (2015) Clinical and microbiological determinants of infection after transrectal prostate biopsy. Clin Infect Dis 60(7):979\u2013987","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2163_CR12","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1093\/jac\/dkt276","volume":"68","author":"DA Williamson","year":"2013","unstructured":"Williamson DA et al (2013) Clinical and molecular correlates of virulence in Escherichia coli causing bloodstream infection following transrectal ultrasound-guided (TRUS) prostate biopsy. J Antimicrob Chemother 68(12):2898\u20132906","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2163_CR13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.juro.2015.03.126","volume":"194","author":"PR Womble","year":"2015","unstructured":"Womble PR et al (2015) A statewide intervention to reduce hospitalizations after prostate biopsy. J Urol 194(2):403\u2013409","journal-title":"J Urol"},{"issue":"5","key":"2163_CR14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/bju.13466","volume":"117","author":"MJ Roberts","year":"2016","unstructured":"Roberts MJ, Doi SA (2016) Prostate biopsy, targeted prophylaxis and infectious complications: a critique of methods used. BJU Int 117(5):719\u2013721","journal-title":"BJU Int"},{"issue":"5","key":"2163_CR15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1179\/joc.2010.22.5.355","volume":"22","author":"S Senol","year":"2010","unstructured":"Senol S et al (2010) Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother 22(5):355\u2013357","journal-title":"J Chemother"},{"issue":"5","key":"2163_CR16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5694\/mja12.11719","volume":"198","author":"MJ Roberts","year":"2013","unstructured":"Roberts MJ et al (2013) Multifocal abscesses due to multiresistant Escherichia coli after transrectal ultrasound-guided prostate biopsy. Med J Aust 198(5):282\u2013284","journal-title":"Med J Aust"},{"issue":"4","key":"2163_CR17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.euf.2016.09.006","volume":"2","author":"H Kandil","year":"2016","unstructured":"Kandil H, Cramp E, Vaghela T (2016) Trends in antibiotic resistance in urologic practice. Eur Urol Focus 2(4):363\u2013373","journal-title":"Eur Urol Focus"},{"issue":"4","key":"2163_CR18","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/cid\/cit704","volume":"58","author":"BJ Gardiner","year":"2014","unstructured":"Gardiner BJ et al (2014) Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis 58(4):e101\u2013e105","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2163_CR19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijantimicag.2013.05.018","volume":"42","author":"S Parker","year":"2013","unstructured":"Parker S et al (2013) What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents 42(4):289\u2013293","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"2163_CR20","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/jac\/dkv067","volume":"70","author":"NJ Rhodes","year":"2015","unstructured":"Rhodes NJ et al (2015) Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. J Antimicrob Chemother 70(7):2068\u20132073","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2163_CR21","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097","journal-title":"PLoS Med"},{"key":"2163_CR22","unstructured":"Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration"},{"key":"2163_CR23","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"key":"2163_CR24","unstructured":"Higgins JPT et al (2016) A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V (eds), Cochrane methods. Cochrane database of systematic reviews. 10(Suppl 1)"},{"issue":"Pt A","key":"2163_CR25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cct.2015.05.009","volume":"45","author":"SA Doi","year":"2015","unstructured":"Doi SA et al (2015) Advances in the meta-analysis of heterogeneous clinical trials I: the inverse variance heterogeneity model. Contemp Clin Trials 45(Pt A):130\u2013138","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"2163_CR26","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2014.10.031","volume":"67","author":"M Perera","year":"2015","unstructured":"Perera M et al (2015) Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol 67(4):704\u2013713","journal-title":"Eur Urol"},{"issue":"2","key":"2163_CR27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/oxfordjournals.aje.a009981","volume":"150","author":"B Takkouche","year":"1999","unstructured":"Takkouche B, Cadarso-Suarez C, Spiegelman D (1999) Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 150(2):206\u2013215","journal-title":"Am J Epidemiol"},{"issue":"Pt A","key":"2163_CR28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cct.2015.05.010","volume":"45","author":"SA Doi","year":"2015","unstructured":"Doi SA et al (2015) Advances in the meta-analysis of heterogeneous clinical trials II: the quality effects model. Contemp Clin Trials 45(Pt A):123\u2013129","journal-title":"Contemp Clin Trials"},{"key":"2163_CR29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-3-642-37131-8_15","volume-title":"Methods of clinical epidemiology","author":"AA Onitilo","year":"2013","unstructured":"Onitilo AA, Doi SAR, Barendregt JJ (2013) Meta-analysis II. In: Williams G, Doi SAR (eds) Methods of clinical epidemiology. Springer Series on Epidemiology and Public Health, Berlin, pp 253\u2013266"},{"issue":"8","key":"2163_CR30","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1017\/S0950268815002885","volume":"144","author":"HY Bennett","year":"2016","unstructured":"Bennett HY et al (2016) The global burden of major infectious complications following prostate biopsy. Epidemiol Infect 144(8):1784\u20131791","journal-title":"Epidemiol Infect"},{"key":"2163_CR31","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002","journal-title":"BMJ"},{"key":"2163_CR32","volume-title":"NICE Decision Support Unit technical support documents, in a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"S Dias","year":"2014","unstructured":"Dias S et al (2014) NICE Decision Support Unit technical support documents, in a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. National Institute for Health and Care Excellence (NICE), London"},{"issue":"3","key":"2163_CR33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.aju.2016.05.003","volume":"14","author":"AM Fahmy","year":"2016","unstructured":"Fahmy AM et al (2016) Fosfomycin antimicrobial prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a prospective randomised study. Arab J Urol 14(3):228\u2013233","journal-title":"Arab J Urol"},{"issue":"6","key":"2163_CR34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.acuro.2014.01.002","volume":"38","author":"F Lista","year":"2014","unstructured":"Lista F et al (2014) Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy. Prospective randomized comparison with ciprofloxacin. Actas Urol Esp 38(6):391\u2013396","journal-title":"Actas Urol Esp"},{"issue":"11\u201312","key":"2163_CR35","doi-asserted-by":"crossref","first-page":"E863","DOI":"10.5489\/cuaj.3068","volume":"9","author":"V Sen","year":"2015","unstructured":"Sen V et al (2015) The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: a prospective, randomized, and controlled clinical study. Can Urol Assoc J 9(11\u201312):E863\u2013E867","journal-title":"Can Urol Assoc J"},{"issue":"2","key":"2163_CR36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00345-016-1867-6","volume":"35","author":"T Cai","year":"2017","unstructured":"Cai T et al (2017) Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative. World J Urol 35(2):221\u2013228","journal-title":"World J Urol"},{"issue":"4","key":"2163_CR37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000342370","volume":"89","author":"S Ong\u00fcn","year":"2012","unstructured":"Ong\u00fcn S, Aslan G, Avkan-Oguz V (2012) The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate. Urol Int 89(4):439\u2013444","journal-title":"Urol Int"},{"issue":"2","key":"2163_CR38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","volume":"29","author":"ME Falagas","year":"2016","unstructured":"Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ (2016) Fosfomycin. Clin Microbiol Rev 29(2):321\u2013347","journal-title":"Clin Microbiol Rev"},{"key":"2163_CR39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2016.12.011","volume":"104","author":"MJ Roberts","year":"2017","unstructured":"Roberts MJ et al (2017) Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches. Urology 104:11\u201321","journal-title":"Urology"},{"issue":"2","key":"2163_CR40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.eururo.2015.05.010","volume":"69","author":"T Cai","year":"2016","unstructured":"Cai T et al (2016) Adherence to European Association of Urology guidelines on prophylactic antibiotics: an important step in antimicrobial stewardship. Eur Urol 69(2):276\u2013283","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-017-2163-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-017-2163-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-017-2163-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T07:33:35Z","timestamp":1519889615000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-017-2163-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,29]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["2163"],"URL":"https:\/\/doi.org\/10.1007\/s00345-017-2163-9","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,29]]}}}